DFX Intelligence
Venture Capital Intelligence
Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.
Firms / SR One
SR One
CandidateUS
no sworn venture fact yet (name or round mention only)
Importance
4
low
Active deployment
33
moderate
Emerging
0
low
Completeness
25
moderate
Freshness
98
high
Research priority
10
low
Identity and regulatory footprint
- Headquarters
- unknown
- Office address
- unknown
- Business phone
- unknown
- Website
- unknown
- SEC adviser type
- unknown
- SEC exemption claimed
- unknown
- Latest Form ADV
- unknown
- Private funds reported
- unknown
- Private fund gross assets
- unknownreported GAV of the funds, the adviser's own number; not fund size, not dry powder
Stated thesis versus observed behaviour
2 observed deals
Stated (the firm’s website)
- Sectors
- not stated or not yet read
- Stages
- not stated or not yet read
- Geography
- not stated
- Check size
- not stated; DFX does not estimate checks from round sizes
Observed (from deals on record)
Stage at participation
series a 50%series b 50%
Stage at first entry
series a 50%series b 50%
Sectors
unknown 100%
lead rate 0%follow-on rate 0%new logos, 12 months 2
Funds and vehicles
1 reported
| Vehicle | Type | Vintage | Lifecycle | Reported GAV | Owners | Form D sold | Latest Form D |
|---|---|---|---|---|---|---|---|
| SR One Capital Fund II-A, LP | Feeder or parallel | 2023 lp reported | Active deployment | unknown | unknown | unknown | unknown |
GAV is the gross asset value the adviser reported on Form ADV for the vehicle, never the fund’s committed size and never dry powder. Form D sold is the amount sold as of the latest filing, never a final close.
Investment team
0 current, 0 departed
No named professional yet. People arrive from Form ADV Schedule A (owners, officers, control persons) and the team page.
Investments on record
2 edges, 2 companies, 0 partner-attributed
| Company | Round | Role | Partner | Round size | This investor | Date | Source |
|---|---|---|---|---|---|---|---|
| Crystalys Therapeutics | Series B · Series B | participant | unknown | $130M | unknown | Jul 22, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
| Immutrin | Series A · Series A | participant | unknown | $87.0M | unknown | Mar 24, 2026 | Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) |
“This investor” is the amount disclosed for this investor alone; it is unknown unless a source said it. The round size is the whole round.
Co-investors
15 relationships from shared deals, counted for the whole firm
Frazier Life Sciences 2 shared · recurring · they led 2Pivotal 1 shared · one timeCormorant Asset Management 1 shared · one timeLightstone Ventures 1 shared · one timeSoleus Capital Management, L.P. 1 shared · one timeKCap Biotechnology Fund 1 shared · one timeWellington Management 1 shared · one timeHBM Healthcare Investments 1 shared · one timePerceptive Xontogeny Venture Funds 1 shared · one timePivotal Life Sciences 1 shared · one timeTrails Edge Capital Partners 1 shared · one timeCatalys Pacific 1 shared · one timeQiming 1 shared · one timeCambridge Enterprise Ventures 1 shared · one timeF-Prime 1 shared · one time
Limited partners
2 disclosed
Timeline
2 dated events
- Dec 31, 2025CalPERS reports SR One Capital Opportunities Fund I, LP: $72,351,563 committed, vintage 2023, net IRR 8.7%, 1.1x
- Dec 31, 2025CalPERS reports SR One Capital Fund II-A, LP: $90,000,000 committed, vintage 2023, net IRR 7.9%, 1.1x
Classification history
- Sep 12, 2026Candidate (candidate, 50%, cls-1)no sworn venture fact yet (name or round mention only)
Evidence
0 observations from 0 sources
Every observation behind this profile, with its source, date and class
| Fact | Value | Effective | Class | Source |
|---|